Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Guifang Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6283-7266; OpenAlex author ID A5010050815. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
10
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: 4 papers · 2024: 1 paper · 2025: 1 paper

Papers 7

  1. Efficacy and Safety of Different Sequences for mFOLFIRINOX (or SOXIRI) and Gemcitabine Plus Albumin-Bound Paclitaxel in Unresectable Pancreatic Cancer. Last author DOI 10.2147/itt.s530434↗
  2. Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2023.12.008↗
  3. Inflammatory bowel disease increases the risk of hepatobiliary pancreatic cancer: A two-sample Mendelian randomization analysis of European and East Asian popu… Last author DOI 10.1002/cam4.6057↗
  4. Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and networ… Last author DOI 10.1007/s00228-022-03441-9↗
  5. Analysis of Risk Factors for Distant Metastasis of Pancreatic Ductal Adenocarcinoma without Regional Lymph Node Metastasis and a Nomogram Prediction Model for … Last author DOI 10.1155/2023/2916974↗
  6. Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer. Last author DOI 10.1177/17588359231186029↗
  7. Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single… Last author DOI 10.3390/curroncol28010023↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xujia Li · 5 shared papers, 2023–2024 · strength 0.99
  2. Feng‐Hua Wang · 4 shared papers, 2020–2025 · strength 0.82
  3. Jinsheng Huang · 4 shared papers, 2023 · strength 0.80
  4. Shengping Li · 3 shared papers, 2023–2024 · strength 0.59
  5. Qi Quan · 3 shared papers, 2020–2024 · strength 0.51
  6. Silan Huang · 1 shared paper, 2025 · strength 0.30
  7. Bokang Cui · 1 shared paper, 2023 · strength 0.20
  8. Miao‐Zhen Qiu · 1 shared paper, 2024 · strength 0.20
  9. Yuhong Li · 1 shared paper, 2024 · strength 0.20
  10. Dongsheng Zhang · 1 shared paper, 2020 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.